North East Florida ENA R/R Myeloma - Feb. 8, 2024

The Role of the ED in Treating Multiple Myeloma in the Era of Novel Immunotherapies

North East Florida ENA Chapter

Thursday, February 8, 2024

5:30 PM CT - Registration/Dinner
6:30 PM ET - Presentation

LIVE VENUE

Maggiano’s Little Italy
Calabria Room

10367 Midtown Parkway St Johns
Jacksonville, FL 32246

R/R Myeloma Form

Name

First Name

Last Name

Profession

Specialty

Please rate your current level of confidence in identifying known treatment-related adverse events (TRAEs) associated with CAR T-cell therapies and bispecific antibodies (BsAbs) in relapsed/refractory multiple myeloma (RRMM) patients.

How often do you currently encounter RRMM patients with potential treatment-related adverse events (TRAEs) associated with CAR T-cell therapies and BsAbs.

How often do you currently administer therapies and/or supportive care for known TRAEs associated with CAR T-cell therapies and BsAbs in RRMM patients.

Virtual Registration

The introduction of CAR T-cell therapies and bispecific antibodies has transformed treatment of multiple myeloma (MM). However, these agents also pose unique safety challenges that may be unfamiliar to busy ED physicians. As more patients receive these immunotherapies, they may increasingly present to the ED for treatment of complications including CRS and ICANS.

ED clinicians must prepare now for this influx by increasing their ability to diagnose and mitigate immunotherapyassociated adverse events. Join one of our distinguished faculty in a live online discussion of the skills needed to manage these complex scenarios and support improved outcomes in MM patients treated with novel immunotherapies.

FACULTY PRESENTER

Joshua Richter, MD

Associate Professor of Medicine
Tisch Cancer Institute
Division of Hematology and Medical Oncology
New York, NY

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.